Stocktoria
Denali Therapeutics Inc. DNLI
Denali Therapeutics Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $330.5M | $108.5M | $48.7M | $335.7M | $26.7M | $129.2M | $0 |
| R&D expense | $418.8M | $396.4M | $423.9M | $358.7M | $265.4M | $212.6M | $193.4M | $143.2M | $74.5M |
| Operating income | -$555.3M | -$487.3M | -$196.7M | -$340.7M | -$295.8M | $62.7M | -$213.2M | -$46.4M | -$90.1M |
| Income tax | $102,000 | $68,000 | $30,000 | $21,000 | -$575,000 | $823,000 | -$351,000 | $0 | $0 |
| Net income | -$512.5M | -$422.8M | -$145.2M | -$326.0M | -$290.6M | $71.1M | -$197.6M | -$36.2M | -$88.2M |
| EPS (diluted) | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 | $0.63 | $-2.07 | $-0.39 | — |
| Operating cash flow | -$412.6M | -$347.7M | -$358.0M | -$244.7M | -$211.4M | $416.2M | -$151.6M | $50.1M | -$76.6M |
| Free cash flow | -$422.1M | -$363.6M | -$370.9M | -$262.5M | -$219.9M | $413.1M | -$169.5M | $46.7M | -$79.5M |
| Cash & equivalents | $205.3M | $175.0M | $127.1M | $218.0M | $293.5M | $507.1M | $79.4M | $77.1M | $218.4M |
| Inventory | $0 | — | — | — | — | — | — | — | — |
| Total assets | $1.1B | $1.4B | $1.2B | $1.5B | $1.4B | $1.6B | $553.2M | $662.0M | $486.7M |
| Total liabilities | $131.1M | $144.5M | $123.0M | $417.8M | $441.9M | $453.7M | $158.3M | $115.1M | $20.9M |
| Shareholders' equity | $1.0B | $1.2B | $1.0B | $1.0B | $962.3M | $1.2B | $394.9M | $546.8M | $465.8M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | -100.0% | +204.7% | +122.9% | -85.5% | +1158.2% | -79.3% | — | — |
| Net income growth | — | — | — | — | -508.5% | — | — | — | — |
| EPS growth | — | — | — | — | -479.4% | — | — | — | — |
| Free cash flow growth | — | — | — | — | -153.2% | — | -462.8% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.